An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)

Key Inclusion Criteria: * Histologically confirmed diagnosis of stage III (unresectable) or stage IV cutaneous melanoma (non-acral lentiginous) with at least 1 lesion that is measurable by RECIST 1.1 criteria and accessible for biopsies * Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 * Adequate hepatic function * Adequate renal function * Adequate bone marrow function * Willing and able to comply with clinic visits and study-related procedures * Provide signed informed consent * Able to understand and complete study-related questionnaires * Anticipated life expectancy \>12 weeks Key Exclusion Criteria: * Ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for immune-related adverse events (irAEs). * Prior treatment with an agent that blocks the programmed death-1/ programmed death-ligand 1 (PD-1/PD-L1 pathway) * Prior treatment with other immune modulating anti-cancer agents, except for remote treatment (\>6 months) in adjuvant setting. * Untreated or active brain metastases or spinal cord compression * Immunosuppressive corticosteroid doses (\>10 mg prednisone daily or equivalent) within 4 weeks prior to the first dose of REGN2810 Other protocol-defined inclusion/exclusion criteria will apply